1-Boc-3-溴-5-硝基-1H-吲唑 | 473416-22-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-Boc-3-溴-5-硝基-1H-吲唑
• 中文别名: 3-溴-5-硝基-1H-吲唑-1-羧酸叔丁酯
• 英文名称: 3-Bromo 5-nitro-indazole-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 3-bromo-5-nitro-1H-1-indazolecarboxylate；1-Boc-3-bromo-5-nitro-1H-indazole；tert-butyl 3-bromo-5-nitroindazole-1-carboxylate
• CAS: 473416-22-7
• 化学式: C₁₂H₁₂BrN₃O₄
• 分子量: 342.149
• InChiKey: BWYOEKHPBGLTHI-UHFFFAOYSA-N

物化性质

• 沸点：
  452.6±48.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-3-bromo-5-nitro-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-3-bromo-5-nitro-1h-indazole
CAS number: 473416-22-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H12BrN3O4
Molecular weight: 342.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-3-溴-5-硝基-1H-吲唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3S)-N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-3-methylsulfanylpyrrolidine-3-carboxamide
  参考文献：
  名称：

  Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology

  摘要：

  Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 mu M h; F% = 0) which precluded further development. In an effort to identify novel ERK inhibitors with improved PK properties with respect to 5, a systematic exploration of sterics and composition at the 3-position of the pyrrolidine led to the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 28 with vastly improved PK (rat AUC PK @10 mpk = 26 mu M h; F% = 70). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.063
• 作为产物：
  描述：

  5-硝基吲唑 在 溴 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-Boc-3-溴-5-硝基-1H-吲唑
  参考文献：
  名称：

  Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology

  摘要：

  Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 mu M h; F% = 0) which precluded further development. In an effort to identify novel ERK inhibitors with improved PK properties with respect to 5, a systematic exploration of sterics and composition at the 3-position of the pyrrolidine led to the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 28 with vastly improved PK (rat AUC PK @10 mpk = 26 mu M h; F% = 70). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.063

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：NUVATION BIO INC

  公开号：WO2021003314A1

  公开（公告）日：2021-01-07

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供异环化合物作为CDK4或CDK6或其他CDK抑制剂。这些化合物可能作为治疗疾病的治疗剂，特别是在肿瘤学方面可能具有特殊用途。
• 一种苯并五元氮杂环衍生物及其应用
  申请人：佛山市晨康生物科技有限公司

  公开号：CN110551104B

  公开（公告）日：2022-04-05

  本发明涉及一种苯并五元氮杂环衍生物，该化合物的化学结构如下式(I)所示；式(I)中，X为N或C；Y为C或N；R1为1‑甲基‑吲哚‑5‑基、1‑甲基‑吲唑‑5‑基、3,4,5‑三甲氧基苯基或对甲基苯基；R2为3,4,5‑三甲氧基苯基、对甲基苯基、1‑甲基‑吲哚‑5‑基、1‑甲基‑吲哚‑4‑基或1‑甲基‑吲哚‑3‑基。本发明所述的化合物能够抑制肿瘤细胞增殖，可用于制备抗肿瘤的药物。
• Novel 1H-indazole compounds
  申请人：Oinuma Hitoshi

  公开号：US20050282880A1

  公开（公告）日：2005-12-22

  The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon group etc.; R 2 , R 4 and R 5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C 1 -C 6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or —NH—CO—, etc.; and Y is a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

  本发明提供了一种新型的1H-吲唑化合物，具有出色的JNK抑制作用。更具体地说，提供了以下公式所表示的化合物，其盐或水合物。其中，R1是C6-C14芳香环烃基等；R2、R4和R5各自独立地表示氢原子、卤原子、氰基等；L是单键或C1-C6烷基等；X是单键或由—CO—NH—或—NH—CO—等表示的基团；Y是C3-C8环烷基、C6-C14芳香环烃基或5-至14成员芳香杂环基等。
• Novel 1h-indazole compound
  申请人：——

  公开号：US20040127538A1

  公开（公告）日：2004-07-01

  The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon group etc.; R 2 , R 4 and R 5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C 1 -C 6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or —NH—CO—, etc.; and Y is a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

  本发明提供了一种具有出色的JNK抑制作用的新型1H-吲唑化合物。更具体地，它提供了以下式子所表示的化合物、其盐或水合物。其中，R1为C6-C14芳香环烃基等；R2、R4和R5各自独立地表示氢原子、卤素原子、氰基等；L为单键或C1-C6烷基等；X为单键或由—CO—NH—或—NH—CO—等表示的基团；Y为C3-C8环烷基、C6-C14芳香环烃基或5-至14-环芳杂环基等。
• Indazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040009968A1

  公开（公告）日：2004-01-15

  The present invention provides compounds of formula I: 1 or a pharmaceutically acceptable derivative thereof, wherein R 1 , R 2 , V 1 , V 2 , and V 3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

  本发明提供了公式I的化合物：1或其药学上可接受的衍生物，其中R1、R2、V1、V2和V3如说明书所述。这些化合物是蛋白激酶的抑制剂，特别是AKT、PKA、PDK1、p70S6K或ROCK激酶的抑制剂，哺乳动物蛋白激酶参与增殖和神经退行性疾病。本发明还提供了包括本发明化合物的制药组合物以及利用这些组合物治疗各种疾病的方法。